Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600E Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06411600
What this trial is testing

Combination Therapy for BRAF-V600E Metastatic CRCm

Who this might be right for
Metastatic Colorectal Cancer
Vall d'Hebron Institute of Oncology 94
Early research (Phase 1)Looking for participantsNCT06102902
What this trial is testing

Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer

Who this might be right for
Metastatic Colorectal AdenocarcinomaRecurrent Colorectal AdenocarcinomaRefractory Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI) 30
Not applicableNo Longer AvailableNCT02416232
What this trial is testing

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Who this might be right for
Melanoma
GlaxoSmithKline
Not applicableLooking for participantsNCT05868629
What this trial is testing

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Who this might be right for
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals 40
Very early researchUnknownNCT01417442
What this trial is testing

BRAF V600E Mutations In Papillary Thyroid Carcinoma

Who this might be right for
Papillary Thyroid Carcinoma
Bezmialem Vakif University 150
Testing effectiveness (Phase 2)Ended earlyNCT03973918
What this trial is testing

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

Who this might be right for
High Grade GliomaBRAF V600EBRAF V600K+4 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Not applicableEnded earlyNCT03593993
What this trial is testing

A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas

Who this might be right for
GliomaBRAF V600EPleomorphic Xantho-Astrocytoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Testing effectiveness (Phase 2)UnknownNCT03727763
What this trial is testing

Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)

Who this might be right for
Colorectal Cancer
Shanghai Changzheng Hospital 30
Large-scale testing (Phase 3)Study completedNCT01584648
What this trial is testing

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

Who this might be right for
Melanoma
Novartis Pharmaceuticals 423
Testing effectiveness (Phase 2)Looking for participantsNCT06653517
What this trial is testing

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

Who this might be right for
AmeloblastomaBRAF V600E Mutation Positive
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University 12
Testing effectiveness (Phase 2)WithdrawnNCT02143050
What this trial is testing

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Who this might be right for
Melanoma
University of Louisville
Large-scale testing (Phase 3)WithdrawnNCT02427893
What this trial is testing

Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma

Who this might be right for
Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Active Not RecruitingNCT05217446
What this trial is testing

Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 108
Testing effectiveness (Phase 2)Ended earlyNCT01978236
What this trial is testing

Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

Who this might be right for
Melanoma and Brain Metastases
GlaxoSmithKline 6
Not applicableUnknownNCT06539702
What this trial is testing

Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.

Who this might be right for
Blood Platelet DisorderBRAF V600EThyroid Nodule+1 more
Saglik Bilimleri Universitesi 120
Testing effectiveness (Phase 2)UnknownNCT04984369
What this trial is testing

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Who this might be right for
CRC
Shanghai Henlius Biotech 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044
What this trial is testing

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Who this might be right for
Melanoma
Pierre Fabre Medicament 815
Testing effectiveness (Phase 2)UnknownNCT03585686
What this trial is testing

A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation

Who this might be right for
Langerhans Cell Histiocytosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 12
Testing effectiveness (Phase 2)UnknownNCT05641493
What this trial is testing

A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Henlius Biotech 49
Next Page